Daniel A Arber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3430088/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>TP53</i> mutation defines a unique subgroup within complex karyotype deÂnovo and therapy-related MDS/AML. Blood Advances, 2022, 6, 2847-2853.	5.2	87
2	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. American Journal of Hematology, 2022, 97, 514-518.	4.1	30
3	GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues. American Journal of Clinical Pathology, 2022, 158, 228-234.	0.7	1
4	How I Diagnose Acute Leukemia of Ambiguous Lineage. American Journal of Clinical Pathology, 2022, 158, 27-34.	0.7	4
5	<i>NPM1</i> exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring. EJHaem, 2022, 3, 962-965.	1.0	2
6	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
7	EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 621-646.	2.8	2
8	Non-hematopoietic neoplastic and pseudoneoplastic lesions of the spleen. Seminars in Diagnostic Pathology, 2021, 38, 159-164.	1.5	3
9	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	5.5	9
10	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology, 2021, 34, 1358-1366.	5.5	8
11	Pathology of the spleen: INTRODUCTION. Seminars in Diagnostic Pathology, 2021, 38, 111.	1.5	1
12	Vascular neoplasms and non-neoplastic vascular lesions of the spleen. Seminars in Diagnostic Pathology, 2021, 38, 154-158.	1.5	6
13	Erythroleukemia: an Update. Current Oncology Reports, 2021, 23, 69.	4.0	6
14	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
15	Lymphoid blast transformation in an MPN with <i>BCR-JAK2</i> treated with ruxolitinib: putative mechanisms of resistance. Blood Advances, 2021, 5, 3492-3496.	5.2	14
16	How I investigate chronic myelomonocytic leukemia. International Journal of Laboratory Hematology, 2020, 42, 101-108.	1.3	9
17	Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Advances, 2020, 4, 4924-4928.	5.2	12
18	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5

DANIEL A ARBER

#	Article	IF	CITATIONS
19	Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). American Journal of Clinical Pathology, 2020, 154, 731-741.	0.7	22
20	Challenges and limitations in the primary diagnosis of Tâ€cell and natural killer cell/Tâ€cell lymphoma in bone marrow biopsy. Histopathology, 2020, 77, 2-17.	2.9	1
21	Diagnosis of classic Hodgkin lymphoma on bone marrow biopsy. Histopathology, 2020, 76, 934-941.	2.9	7
22	Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808.	4.1	26
23	Aggressive B ell lymphomas with a primary bone marrow presentation. Histopathology, 2020, 77, 369-379.	2.9	4
24	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422.	1.3	21
25	Myelodysplastic/Myeloproliferative Neoplasms. , 2020, , 162-180.		0
26	The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. Seminars in Hematology, 2019, 56, 90-95.	3.4	48
27	Genetic Testing in the Diagnosis and Biology of Acute Leukemia. American Journal of Clinical Pathology, 2019, 152, 322-346.	0.7	13
28	Update on the pathologic diagnosis of chronic myelomonocytic leukemia. Modern Pathology, 2019, 32, 732-740.	5.5	18
29	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	5.5	25
30	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	3.5	93
31	Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2019, 20, 15.	3.0	21
32	High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 740-748.	1.2	11
33	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	5.5	50
34	A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 416-422.	1.2	15
35	Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis. American Journal of Surgical Pathology, 2018, 42, 885-890.	3.7	19
36	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880.	5.5	3

DANIEL A ARBER

#	Article	IF	CITATIONS
37	Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology, 2018, 31, 690-704.	5.5	35
38	Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. Archives of Pathology and Laboratory Medicine, 2017, 141, 1342-1393.	2.5	88
39	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.9	210
40	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	3.5	62
41	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq1 1 0.7 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	784314 rgB 5.5	T /Overlock 1 52
42	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology, 2017, 148, 49-57.	0.7	18
43	Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Modern Pathology, 2017, 30, 382-392.	5.5	43
44	Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2017, 141, 1101-1106.	2.5	11
45	Revisiting erythroleukemia. Current Opinion in Hematology, 2017, 24, 146-151.	2.5	15
46	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
47	Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. Human Pathology, 2016, 55, 39-43.	2.0	18
48	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405.	1.4	7,429
49	A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Modern Pathology, 2016, 29, 1212-1220.	5.5	46
50	Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Modern Pathology, 2016, 29, 996-1003.	5.5	12
51	Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology American Society of Hematology Education Program, 2015, 2015, 294-298.	2.5	34
52	Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using highâ€resolution arrayâ€based comparative genomic hybridization. American Journal of Hematology, 2015, 90, E151-2.	4.1	0
53	The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma. Human Pathology, 2015, 46, 629-633.	2.0	8
54	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1116-25.	7.1	307

DANIEL A ARBER

#	Article	IF	CITATIONS
55	Primary Gastric Hodgkin's Lymphoma: An Extremely Rare Entity and A Diagnostic Challenge. Digestive Diseases and Sciences, 2015, 60, 2923-2926.	2.3	5
56	Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Modern Pathology, 2015, 28, 706-714.	5.5	114
57	Acute Myeloid Leukemia With Monosomal Karyotype. American Journal of Clinical Pathology, 2014, 142, 190-195.	0.7	20
58	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	1.4	192
59	Mixed Phenotype Acute Leukemia. American Journal of Clinical Pathology, 2014, 142, 803-808.	0.7	62
60	STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica, 2014, 99, e105-e105.	3.5	37
61	Challenges in Consolidated Reporting of Hematopoietic Neoplasms. Surgical Pathology Clinics, 2013, 6, 795-806.	1.7	7
62	Why Is Hematopathology so Complicated?. Surgical Pathology Clinics, 2013, 6, ix.	1.7	0
63	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	1.4	0
64	Immature T-Cell Populations in Lymph Nodes of Castleman Disease and Angioimmunoblastic T-Cell Lymphoma Suggest Alternate Sites of T-Cell Development,. Blood, 2011, 118, 3238-3238.	1.4	0
65	Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. Surgical Pathology Clinics, 2010, 3, 1153-1164.	1.7	15
66	2008 WHO Classification of Pediatric AML Blood, 2010, 116, 1044-1044.	1.4	0
67	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status–Based Treatment Stratification. Blood, 2010, 116, 3313-3313.	1.4	0
68	Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood, 2009, 113, 1906-1908.	1.4	149
69	The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 2009, 114, 937-951.	1.4	3,864
70	AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome Blood, 2009, 114, 2638-2638.	1.4	1
71	Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System Blood, 2008, 112, 922-922.	1.4	0
72	Bone Marrow Biopsy Involvement by Non-Hodgkin's Lymphoma. American Journal of Surgical Pathology, 2005, 29, 1549-1557.	3.7	119